Skincare company BeautyHealth (NASDAQ:SKIN) will be announcing earnings results tomorrow afternoon. Here’s what you need to know.

BeautyHealth beat analysts’ revenue expectations by 6.4% last quarter, reporting revenues of $78.8 million, down 19.1% year on year. It was a strong quarter for the company, with a solid beat of analysts’ EBITDA estimates.

Is BeautyHealth a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting BeautyHealth’s revenue to decline 20.2% year on year to $77.28 million, a further deceleration from the 1.4% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.09 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BeautyHealth has missed Wall Street’s revenue estimates three times over the last two years.

Looking at BeautyHealth’s peers in the personal care segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Olaplex’s revenues decreased 9.8% year on year, beating analysts’ expectations by 14.4%, and The Honest Company reported revenues up 10.6%, topping estimates by 3.1%. Olaplex traded up 20.4% following the results while The Honest Company was down 12%.

Read our full analysis of Olaplex’s results here and The Honest Company’s results here.

There has been positive sentiment among investors in the personal care segment, with share prices up 3.9% on average over the last month. BeautyHealth is down 17.9% during the same time and is heading into earnings with an average analyst price target of $1.72 (compared to the current share price of $1.15).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.